[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"palmoplantar-pustulosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:palmoplantar-pustulosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,66,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100609810","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-bimekizumab-in-study-participants-with-palmoplantar-pustulosis-100609810",false,"NCT07219420","A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis","BeSeen","Inclusion Criteria:\n\n* At least 18 years of age inclusive, at the time of signing the informed consent form (ICF)\n* Have a palmoplantar pustulosis (PPP) diagnosis for at least 24 weeks prior to the Screening Visit\n* Have PPPASI ≥12 at the Screening Visit and Baseline Visit\n* Have PPP-IGA ≥3 at the Screening Visit and Baseline Visit\n* Have pustules on the palms of the hands and\u002For soles of the feet at the Screening Visit and Baseline Visit, defined as pustule severity ≥2 and having more than 5 active pustules\n* Participant must be a candidate for systemic therapy or phototherapy\n\nExclusion Criteria:\n\n* Has PPP symptoms which improve significantly between the Screening Visit and Baseline Visit, defined as a reduction in the PPPASI score\n* Has the following: palmoplantar PSO (plaque PSO on palms\u002Fsoles), guttate PSO, erythrodermic PSO (EP), generalized pustular PSO (GPP), Acrodermatitis continua of Hallopeau (ACH), atopic dermatitis, dyshidrotic eczema or chronic hand eczema.\n* Has drug-induced PSO (eg, first onset or current exacerbation due to beta blockers, calcium channel inhibitors, lithium, or tumor necrosis factor \\[TNF\\] inhibitor) or drug-induced pustular PSO (eg, acute generalized exanthematous pustulosis, acute localized exanthematous pustulosis)\n* Has cutaneous lesions that may interfere with the evaluation of the affected area and\u002For evaluation of the severity of PPP\n* Is taking or has taken prohibited or restricted medications without meeting the mandatory discontinuation or stability period relative to the Baseline Visit\n* Is taking or has ever taken an interleukin (IL)-17A\u002FIL-17F inhibitor, including bimekizumab, or has participated in a bimekizumab investigational study","ALL","18 Years",{"count":20,"type":21},320,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).",[27],"Palmoplantar Pustulosis",[29],"Bimekizumab, PPP","RECRUITING","2026-06-18",{"date":33,"type":34},"2026-06-22","ACTUAL",{"date":36,"type":34},"2025-11-14",{"date":38,"type":21},"2029-11-22",{"name":40,"class":41},"UCB Biopharma SRL","INDUSTRY",77,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100593958","phase-2-a-16-week-trial-to-investigate-the-efficacy-and-safety-of-delgocitinib-cream-20-mgg-in-adult-participants-with-mild-to-severe-palmoplantar-pustulosis-100593958","NCT07013201","A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg\u002Fg in Adult Participants With Mild to Severe Palmoplantar Pustulosis","A Proof-of-concept Phase 2a, Double-blind, 2-arm Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream 20 mg\u002Fg Compared With Cream Vehicle During a 16-week Treatment Period in Adult Subjects With Mild to Severe Palmoplantar Pustulosis","Inclusion Criteria:\n\n* Signed and dated informed consent has been obtained prior to any protocol-related procedures.\n* Age 18 years or above at the time of informed consent signing.\n* Participant is able to comply with clinic visits and trial requirements and procedures, as assessed by the investigator.\n* Diagnosis of PPP in accordance with the consensus diagnostic criteria established by European Rare and Severe Psoriasis Expert Network: primary, persistent (\\>3 months duration), sterile, macroscopically visible pustules on the palms and\u002For soles, with or without plaque psoriasis elsewhere on the body.\n* Confirmed PPP by central evaluation of photographs taken at screening.\n* Mild to severe PPP current condition defined by:\n\n  * Disease duration of PPP of \\>6 months before randomisation.\n  * PPP-PGA of at least mild severity (PPP-PGA ≥2) at screening and baseline.\n  * PPPASI ≥8 at screening and baseline.\n* Presence of ≥5 well-demarcated fresh pustules (white or yellow pustules) in total across all affected areas at screening and baseline.\n* Participants with prior experiences of inadequate response with topical corticosteroid(s) (TCS) or for whom TCS are inadvisable, as judged by the investigators.\n* A woman of childbearing potential must use an acceptable form of birth control throughout the trial up until the last administration of investigational medicinal product (IMP).\n\nExclusion Criteria:\n\n* Presence or known history of drug-induced PPP (e.g., a new onset of PPP or an exacerbation of PPP from beta blockers, calcium channel blockers, lithium, or biologic therapy including infliximab, adalimumab, or etanercept).\n* Presence of acrodermatitis continua of Hallopeau.\n* Active dermatologic condition that could confound the diagnosis of PPP or interfere with assessment of the IMP, as assessed by the investigator.\n* Clinically significant infection on the palms or soles.\n* Concurrent plaque psoriasis covering \\>5% of body surface area.\n* Clinically significant infection within 4 weeks prior to baseline, which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the IMP, or reduce the participant's ability to participate in the trial. Clinically significant infections are defined as:\n\n  * A systemic infection.\n  * A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.\n* History of any known primary immunodeficiency disorder, including a positive human immunodeficiency virus test at screening, or the participant taking antiretroviral medications as determined by medical history and\u002For the participant's verbal report.\n* Major surgery within 8 weeks prior to screening or planned in-patient surgery or hospitalisation during the trial period.\n* Any documented active or suspected malignancy, or history of malignancy within 5 years prior to screening, except basal cell carcinoma of the skin, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix appropriately treated before the baseline visit.\n* Any disorder that is not stable and could:\n\n  * Affect the safety of the participant throughout the trial.\n  * Impede the participant's ability to complete the trial. Examples include, but are not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, immunological, and psychiatric disorders, as well as major physical impairment.\n* Any clinically significant abnormal finding occurring during the screening period and\u002For observed at the baseline visit that may put the participant at risk due to their participation in the trial or could influence the participant's ability to complete the trial.\n* Positive hepatitis B surface antigen and\u002For hepatitis B core antibody and positive hepatitis B virus DNA (participants who have tested positive for hepatitis B core antibody are eligible if tests for hepatitis B surface antigen and hepatitis B virus DNA are negative) or positive hepatitis C virus antibody serology confirmed by hepatitis C virus RNA at screening.\n* Known or suspected hypersensitivity to any component(s) of the IMP.\n* Current or recent chronic alcohol or drug abuse, or any other condition associated with poor compliance as judged by the investigator.\n* Women who are pregnant or lactating.\n* Systemic treatment within 4 weeks prior to baseline with immunosuppressive drugs (e.g., methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g., acitretin), tyrosine kinase inhibitors, phosphodiesterase-4 inhibitors, or corticosteroids (steroid eye drops and inhaled or intranasal steroids in the doses recommended in the product prescribing information for the treatment of allergic conjunctivitis, asthma, or rhinitis are allowed).\n* Use of tanning beds or phototherapy (e.g., ultraviolet B \\[UVB\\], ultraviolet A1 \\[UVA1\\], psoralen ultraviolet A \\[PUVA\\]) on the palms or soles within 4 weeks prior to baseline.\n* Use of systemic or topical janus kinase inhibitors (including delgocitinib\u002FLEO 124249) within 4 weeks prior to baseline.\n* Cutaneously applied treatment with immunomodulators (e.g., phosphodiesterase-4 \\[PDE-4\\] inhibitors, pimecrolimus, tacrolimus, tapinarof, vitamin D3 derivatives) or TCS on the palms or soles within 2 weeks prior to baseline.\n* Use of systemic antibiotics or cutaneously applied antibiotics on the palms or soles within 2 weeks prior to baseline.\n* Other transdermal or cutaneously applied therapy on the palms or soles (except for the use of the participant's own non-medicated emollients) within 1 week prior to baseline.\n* Cutaneously applied treatments in regions other than the palms or soles, which could interfere with clinical trial evaluations or pose a safety concern (excluding treatments for psoriasis patches or other non-exclusionary skin conditions, if needed) within 1 week prior to baseline.\n* Treatment with any marketed biological therapy or investigational biologic agents:\n\n  * Any cell-depleting agents, including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.\n  * Other biologics, including but not limited to secukinumab, ustekinumab, tildrakizumab, ixekizumab, risankizumab, guselkumab, and tumour necrosis factor (TNF)-alpha inhibitors: within 3 months or 5 half-lives, whichever is longer, prior to baseline.\n* Treatment with any non-marketed drug substance (i.e., an agent that has not yet been made available for clinical use following registration) within the last 4 weeks prior to baseline or 5 half-lives, whichever is longer.\n* Current participation in any other interventional clinical trial.\n* Previously randomised in this clinical trial.\n* Previously randomised in a clinical trial with delgocitinib.\n* Employees of the trial site, or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.",{"count":51,"type":21},135,[53],"PHASE2","The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg\u002Fg compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.",[27],"2026-06-04",{"date":58,"type":34},"2026-06-05",{"date":60,"type":34},"2025-09-11",{"date":62,"type":21},"2026-12-14",{"name":64,"class":41},"LEO Pharma",38,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100635420","picankibart-in-palmoplantar-pustulosis-100635420","NCT07552454","Picankibart in Palmoplantar Pustulosis","Efficacy and Safety of Picankibart in the Treatment of Moderate-to-Severe Palmoplantar Pustulosis: A Prospective, Single-Arm, Open-Label Clinical Study","Inclusion Criteria:\n\n* Aged 18-65 years, regardless of gender. Patients with a confirmed diagnosis of palmoplantar pustulosis based on clinical manifestations and\u002For skin histopathology.\n\nFailed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions.\n\nConsidered suitable for treatment with picankibart as assessed by the clinician.\n\nVoluntarily participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with active hepatitis B, hepatitis C, or tuberculosis. Pregnant patients or those planning pregnancy within 6 months. Subjects unable to comply with follow-up as required by the study protocol. Other conditions deemed unsuitable for this study.","65 Years",{"count":75,"type":21},60,[77],"NA","1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to enroll 60 eligible subjects.\n2. Study Subjects\n\nInclusion Criteria\n\n1. Aged 18-65 years, regardless of gender.\n2. Patients with a confirmed diagnosis of palmoplantar pustulosis based on clinical manifestations and\u002For skin histopathology.\n3. Failed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions.\n4. Considered suitable for treatment with Picankibart as assessed by the clinician.\n5. Voluntarily participate in the study and provide written informed consent.\n\nExclusion Criteria\n\n1. Patients with active hepatitis B, hepatitis C, or tuberculosis.\n2. Pregnant patients or those planning pregnancy within 6 months.\n3. Subjects unable to comply with follow-up as required by the study protocol.\n4. Other conditions deemed unsuitable for this study.\n\nWithdrawal Criteria\n\n1. Subjects may withdraw from the study at any time for any reason.\n2. Occurrence of a serious adverse event or intolerable adverse event.\n3. Development of any item listed in the exclusion criteria during the study.\n4. The investigator may decide subject withdrawal for medical reasons.",[27],"2026-04-20",{"date":82,"type":34},"2026-04-27",{"date":84,"type":21},"2026-04-15",{"date":86,"type":21},"2027-12-31",{"name":88,"class":89},"Xijing Hospital","OTHER",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":90},"100515705","collection-of-samples-from-subjects-with-various-skin-conditions-and-healthy-volunteers-100515705","NCT05994976","Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers","Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers for Molecular Characterization of Inflammatory Skin Diseases","Inclusion Criteria:\n\nAll subjects:\n\n1. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.\n2. Subject must be willing to comply with all study procedures and must be available for the duration of the study.\n\n   Healthy volunteers:\n3. Male or female subject aged 18 years or older, at the time of consent.\n4. Subject is in good general health, according to the investigator's judgment.\n\n   Subjects with Acne:\n5. Male or female subject aged 18 to 45 years old, inclusive, at the time of consent.\n\n   Subjects with AD:\n6. Male or female subject aged 18 years or older, at the time of consent.\n7. Subject has clinically confirmed diagnosis of active AD, according to Hanifin and Rajka criteria.\n\n   Subjects with CHE:\n8. Male or female subject aged 18 years or older, at the time of consent.\n9. Subject has at least a 6-month history of CHE before Screening (information obtained from medical chart or subject's physician, or directly from the subject).\n\n   Subjects with HS:\n10. Male or female subject aged 18 years or older, at the time of consent.\n11. Subject has a clinically confirmed diagnosis of active HS with a disease duration of ≥ 6 months before screening as determined by the investigator through subject interview and\u002For review of the medical history.\n\n    Subjects with PPP:\n12. Male or female subject aged 18 years or older at the time of consent.\n13. Subject has at least a 6-month history of PPP as defined by the presence of pustules on palms and\u002For soles, but without evidence of infection on palms and soles (information obtained from medical chart or subject's physician, or directly from the subject).\n\n    Subjects with psoriasis:\n14. Male or female subject aged 18 years or older, at the time of consent.\n\nExclusion Criteria:\n\nAll subjects:\n\n1. Subject is a female who is pregnant or who is planning to become pregnant during the study.\n2. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.",true,{"count":100,"type":21},500,"OBSERVATIONAL","The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.",[104,105,106,107,108,27],"Acne","Atopic Dermatitis","Chronic Hand Eczema","Hidradenitis Suppurativa","Plaque Psoriasis","2026-03-25",{"date":111,"type":34},"2026-03-30",{"date":113,"type":34},"2023-10-17",{"date":115,"type":21},"2028-08",{"name":117,"class":89},"Innovaderm Research Inc."]